BiotechTube

HRS-4642 + AG + HRS-4642 placebo + AG

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

Conditions

KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

Trial Timeline

Dec 1, 2025 → Apr 1, 2029

NCT ID
NCT07232875

About HRS-4642 + AG + HRS-4642 placebo + AG

HRS-4642 + AG + HRS-4642 placebo + AG is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07232875. Target conditions include KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting.

What happened to similar drugs?

0 of 1 similar drugs in KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting were approved

Approved (0) Terminated (0) Active (1)
🔄AMG 510 + DocetaxelAmgenPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07232875Phase 3Recruiting

Competing Products

20 competing products in KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

See all competitors
ProductCompanyStageHype Score
HRS-4642 + Adebrelimab + SHR-9839 + Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection + Cetuximab Solution for InfusionJiangsu Hengrui MedicinePhase 1/2
36
HRS-6093Jiangsu Hengrui MedicinePhase 1
36
HRS-4642Jiangsu Hengrui MedicinePhase 1
33
Pembrolizumab + TrametinibMerckPhase 1
29
Opnurasib + TNO155 + trametinib + cetuximab + tislelizumabNovartisPhase 1/2
39
JDQ443 + TNO155 + tislelizumabNovartisPhase 1/2
36
JDQ443 + trametinib + Ribociclib + cetuximabNovartisPhase 1/2
36
JDQ443NovartisPhase 2
39
Trametinib + Anlotinib + TislelizumabNovartisPhase 1/2
39
AMG 510AmgenPhase 1
33
AMG 510 + DocetaxelAmgenPhase 3
44
Epirubicine, Oxaliplatin, Capecitabine, PanitumumabAmgenPhase 2
27
AMG 410 + Pembrolizumab + PanitumumabAmgenPhase 1
36
sotorasib + Anti PD-1/L1 + MidazolamAmgenPhase 1/2
36
MEK162 and mFOLFIRIPfizerPhase 1
29
IBI351+AK112Innovent BiologicsPhase 2
42
GFH925Innovent BiologicsPhase 1/2
32
Momelotinib (MMB) + TrametinibGSK plcPhase 1
21
BAY3498264BayerPhase 1
33
ARV-806ArvinasPhase 1/2
33